These are challenging times for even the best medical technology companies. Insurance companies, hospitals and national governments are pushing back hard on pricing, patient visits are down, and innovation seems stifled between modest clinical progress and a considerably more conservative FDA. Not surprisingly, then, Medtronic (NYSE:MDT) is delivering much less growth than long-term investors are accustomed to, and the near-term outlook is not looking especially strong.

The real question, though, is whether Medtronic can pull out of this rut. Even just a bit more growth at the top line would make this stock a value, but stagnant markets and the turmoil of the transition to a new CEO could keep a lid on the shares in the near term.

A Weak End to the Fiscal Year
Analysts were not expecting a great fiscal fourth quarter, but Medtronic's results were weak nonetheless. Reported revenue was flat on a constant currency basis, though adjusting for the extra week in the year-ago quarter would have bumped the growth rate to 2%. As this quarter shows, foreign sales are becoming increasingly important to Medtronic's growth. Foreign sales were up 7% (constant currency) to just under $2 billion, with emerging market growth coming in at 20%.

The company's largest business, cardiac rhythm management, did not impress. Sales were down 9% overall, led by an especially weak 14% decline in U.S. ICD (implantable cardiac defibrillator) sales. Even granting that CRM sales are not great across the industry, Medtronic does seem to be paying for its decision to stop doing business with Novation, a major purchasing organization. St. Jude (NYSE:STJ) quickly picked up where Medtronic left off, and it stands to reason that Novation would be direct CRM business toward St. Jude products. (For more, see Can St. Jude Live Up To Newfound Expectations?)

Spine was also an area of weakness, as sales dropped 2%. Here, too, is a case of a weak overall industry. While a few companies like Nuvasive (Nasdaq:NUVA), Biomet, Orthofix (Nasdaq:OFIX) and Johnson & Johnson (NYSE:JNJ) are showing relatively better performance, the market as a whole is weak right now.

In contrast, Medtronic did see some strength in stents - a market where Abbott (NYSE:ABT) still does pretty well - and diabetes. Unfortunately, the company is not doing so well overall with its profitability. Gross margin slipped about 80 basis points, and adjusted operating income fell about 8% from last year.

Where Does The Company Go From Here?
On one hand, it seems easy to argue that Medtronic will snap back once the economy gets a little better and patients go back to seeing their doctor. That may be true, but it seems much less likely that insurance companies and hospitals will ease up on pricing.

It is also worth pondering whether Medtronic can still wring enough growth out of its core businesses. It's true that the American population continues to age, but it is also true that doctors have started to pull back from implanting ICDs as enthusiastically as before. Elsewhere, competitive moves (like the merger of JNJ and Synthes) will present new pressures in markets like spine care. (For more, see JNJ and Synthes: A Good Deal With Some Questions.)

The Bottom Line
Investors who think that Medtronic cannot grow anymore would be well advised to remember that markets like drug-coated stents, transcatheter valves, neuromodulation, continuous glucose monitoring and kyphoplasty hardly existed 10 years ago. Spending over $1.5 billion a year in R&D gives Medtronic a better-than-average chance of being a player in many of the next-generation markets - markets that may only exist in the minds of engineers and surgeons today.

That said, hope of better growth should never be more than a part of an investment thesis. Looking at the real numbers, Medtronic's shares do not seem to be incorporating much in the way of future growth expectations. As long as Medtronic can tread water and grow with average procedure counts, and hold the line of free cash flow conversion, the shares seem worth a look for patient value investors. (For more, see A Checklist For Successful Medical Technology Investment.)

Use the Investopedia Stock Simulator to trade the stocks mentioned in this stock analysis, risk free!

Related Articles
  1. Personal Finance

    A Day in the Life of an Equity Research Analyst

    What does an equity research analyst do on an everyday basis?
  2. Mutual Funds & ETFs

    ETF Analysis: PowerShares S&P 500 Downside Hedged

    Find out about the PowerShares S&P 500 Downside Hedged ETF, and learn detailed information about characteristics, suitability and recommendations of it.
  3. Mutual Funds & ETFs

    ETF Analysis: iShares Morningstar Small-Cap Value

    Find out about the Shares Morningstar Small-Cap Value ETF, and learn detailed information about this exchange-traded fund that focuses on small-cap equities.
  4. Mutual Funds & ETFs

    ETF Analysis: ProShares Large Cap Core Plus

    Learn information about the ProShares Large Cap Core Plus ETF, and explore detailed analysis of its characteristics, suitability and recommendations.
  5. Mutual Funds & ETFs

    ETF Analysis: iShares Core Growth Allocation

    Find out about the iShares Core Growth Allocation Fund, and learn detailed information about its characteristics, suitability and recommendations.
  6. Mutual Funds & ETFs

    ETF Analysis: iShares MSCI USA Minimum Volatility

    Learn about the iShares MSCI USA Minimum Volatility exchange-traded fund, which invests in low-volatility equities traded on the U.S. stock market.
  7. Stock Analysis

    Should You Follow Millionaires into This Sector?

    Millionaire investors—and those who follow them—should take another look at the current economic situation before making any more investment decisions.
  8. Professionals

    What to do During a Market Correction

    The market has corrected...now what? Here's what you should consider rather than panicking.
  9. Mutual Funds & ETFs

    ETF Analysis: WisdomTree SmallCap Earnings

    Discover the WisdomTree Small Cap Earnings ETF, a fund with a special focus on small-cap and micro-cap stocks with positive earnings.
  10. Mutual Funds & ETFs

    ETF Analysis: iShares US Regional Banks

    Obtain information and analysis of the iShares US Regional Banks ETF for investors seeking particular exposure to regional bank stocks.
RELATED TERMS
  1. Equity

    The value of an asset less the value of all liabilities on that ...
  2. Profit Margin

    A category of ratios measuring profitability calculated as net ...
  3. Quarter - Q1, Q2, Q3, Q4

    A three-month period on a financial calendar that acts as a basis ...
  4. Debt Ratio

    A financial ratio that measures the extent of a company’s or ...
  5. Price-Earnings Ratio - P/E Ratio

    The Price-to-Earnings Ratio or P/E ratio is a ratio for valuing ...
  6. Net Present Value - NPV

    The difference between the present values of cash inflows and ...
RELATED FAQS
  1. What is the formula for calculating compound annual growth rate (CAGR) in Excel?

    The compound annual growth rate, or CAGR for short, measures the return on an investment over a certain period of time. Below ... Read Full Answer >>
  2. What is the difference between called-up share capital and paid-up share capital?

    The difference between called-up share capital and paid-up share capital is investors have already paid in full for paid-up ... Read Full Answer >>
  3. When does the fixed charge coverage ratio suggest that a company should stop borrowing ...

    Since the fixed charge coverage ratio indicates the number of times a company is capable of making its fixed charge payments ... Read Full Answer >>
  4. Why would a corporation issue convertible bonds?

    A convertible bond represents a hybrid security that has bond and equity features; this type of bond allows the conversion ... Read Full Answer >>
  5. What is the difference between the return on total assets and an interest rate?

    Return on total assets (ROTA) represents one of the profitability metrics. It is calculated by taking a company's earnings ... Read Full Answer >>
  6. How does additional paid in capital affect retained earnings?

    Both additional paid-in capital and retained earnings are entries under the shareholders' equity section of a company's balance ... Read Full Answer >>

You May Also Like

COMPANIES IN THIS ARTICLE
Trading Center
×

You are using adblocking software

Want access to all of Investopedia? Add us to your “whitelist”
so you'll never miss a feature!